Business Acquisition Purchase Price Allocation Research And Development Expense Liability

No definition available.

Name:	sppi_BusinessAcquisitionPurchasePriceAllocationResearchAndDevelopmentExpenseLiability
Namespace Prefix:	sppi_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Development Cost Differential

+ References

No definition available.

+ Details

Name:	sppi_DevelopmentCostDifferential
Namespace Prefix:	sppi_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Fair value of the development cost differential contingent obligation.

+ References

No definition available.

+ Details

Name:	sppi_DevelopmentCostDifferentialContingentObligationFairValue
Namespace Prefix:	sppi_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Development cost differential maximum payment

+ References

No definition available.

+ Details

Name:	sppi_DevelopmentCostDifferentialMaximumPayment
Namespace Prefix:	sppi_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Potential Milestone Payments

+ References

No definition available.

+ Details

Name:	sppi_PotentialMilestonePayments
Namespace Prefix:	sppi_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Potential Share Of Joint Development Costs

+ References

No definition available.

+ Details

Name:	sppi_PotentialShareOfJointDevelopmentCosts
Namespace Prefix:	sppi_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Share Of Joint Development costs

+ References

No definition available.

+ Details

Name:	sppi_ShareOfJointDevelopmentCosts
Namespace Prefix:	sppi_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

For unclassified balance sheet, amounts due from customers or clients for goods or services that have been delivered or sold in the normal course of business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.9)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name:	us-gaap_AccountsReceivableGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Total costs of sales and operating expenses for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_CostsAndExpenses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 25

-Paragraph 20

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=29652012&loc=d3e28680-109314

+ Details

Name:	us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred tax liability attributable to taxable temporary differences from other capitalized costs not separately disclosed.

+ References

+ Details

Name:	us-gaap_DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Fair value portion of contractual obligation to pay money on demand or on fixed or determinable dates.

+ References

No definition available.

+ Details

Name:	us-gaap_LoansPayableFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Mundipharma Agreements - Additional Information (Detail) (USD $)		6 Months Ended		1 Months Ended	3 Months Ended	6 Months Ended		3 Months Ended	6 Months Ended
	Sep. 05, 2012	Jun. 30, 2013 Maximum [Member] Regulatory [Member]	Jun. 30, 2013 Maximum [Member] Commercial progress- and sales-dependent [Member]	May 29, 2013 Mundipharma [Member]	Jun. 30, 2013 Mundipharma [Member]	Jun. 30, 2013 Mundipharma [Member]	May 31, 2013 Mundipharma [Member]	Jun. 30, 2013 Mundipharma [Member] Reimbursed joint development cost [Member]	Jun. 30, 2013 Mundipharma [Member] Reimbursed joint development cost [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments		$ 16,000,000	$ 107,000,000
Deferred development cost	12,300,000
Company determined development payment				7,000,000
Development cost liability					18,700,000	18,700,000
Development cost differential, maximum payment								15,000,000	15,000,000
License and contract revenue								268,000	589,000
Portion of joint development costs incurred by the parties					40.00%
Potential portion of joint development costs incurred by the parties						50.00%
Developmental cost differential amount							12,099
Remaining developmental cost					18,700,000	18,700,000
Fair value of related contingent payment obligation to research and development				0
Difference in related contingent payment				2,400,000
Accounts receivable					$ 24,000	$ 24,000